Detalles de la búsqueda
1.
Discovery of a novel 2-spiroproline steroid mimetic scaffold for the potent inhibition of 11ß-HSD1.
Bioorg Med Chem Lett
; 73: 128884, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35835377
2.
Discovery of 1'-(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3'-pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11ß-HSD1 using a scaffold-hopping approach.
Bioorg Med Chem Lett
; 69: 128782, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35537608
3.
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Clin Immunol
; 218: 108517, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32585295
4.
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy.
J Pharmacol Exp Ther
; 374(1): 211-222, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32345620
5.
INCB040093 Is a Novel PI3Kδ Inhibitor for the Treatment of B Cell Lymphoid Malignancies.
J Pharmacol Exp Ther
; 364(1): 120-130, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29127109
6.
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2.
J Med Chem
; 67(4): 3112-3126, 2024 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38325398
7.
Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors.
ACS Med Chem Lett
; 14(1): 5-10, 2023 Jan 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36655125
8.
Potent and Selective Biaryl Amide Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).
ACS Med Chem Lett
; 14(1): 116-122, 2023 Jan 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36655134
9.
Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach.
ACS Med Chem Lett
; 14(3): 312-318, 2023 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36923909
10.
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Blood
; 115(15): 3109-17, 2010 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20130243
11.
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
J Immunol
; 184(9): 5298-307, 2010 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20363976
12.
Discovery of 5,7-Dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones as Highly Selective CDK2 Inhibitors.
ACS Med Chem Lett
; 13(11): 1797-1804, 2022 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36385925
13.
Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2.
ACS Med Chem Lett
; 13(7): 1159-1164, 2022 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35859885
14.
Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3.
J Med Chem
; 65(22): 15433-15442, 2022 11 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36356320
15.
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.
Cancer Discov
; 12(6): 1482-1499, 2022 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35254416
16.
Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
J Pharmacol Exp Ther
; 338(1): 228-39, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21459966
17.
Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifs.
Bioorg Med Chem Lett
; 21(6): 1827-31, 2011 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21316220
18.
Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.
Bioorg Med Chem Lett
; 21(5): 1442-6, 2011 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21295478
19.
Discovery of ((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profile.
Bioorg Med Chem Lett
; 21(9): 2626-30, 2011 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21315584
20.
Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream.
Pharmaceutics
; 13(7)2021 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34371735